Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Silence Therapeutics (SLNCF) Shares Outstanding (Diluted Average) (2022 - 2025)

Historic Shares Outstanding (Diluted Average) for Silence Therapeutics (SLNCF) over the last 4 years, with Q3 2025 value amounting to $141.7 million.

  • Silence Therapeutics' Shares Outstanding (Diluted Average) fell 2276.09% to $141.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $141.7 million, marking a year-over-year decrease of 2276.09%. This contributed to the annual value of $138.8 million for FY2024, which is 46.36% up from last year.
  • According to the latest figures from Q3 2025, Silence Therapeutics' Shares Outstanding (Diluted Average) is $141.7 million, which was down 2276.09% from $141.7 million recorded in Q2 2025.
  • In the past 5 years, Silence Therapeutics' Shares Outstanding (Diluted Average) ranged from a high of $183.5 million in Q3 2024 and a low of $113.3 million during Q4 2022
  • Over the past 4 years, Silence Therapeutics' median Shares Outstanding (Diluted Average) value was $141.7 million (recorded in 2025), while the average stood at $149.2 million.
  • As far as peak fluctuations go, Silence Therapeutics' Shares Outstanding (Diluted Average) soared by 2191.37% in 2023, and later plummeted by 2276.09% in 2025.
  • Over the past 4 years, Silence Therapeutics' Shares Outstanding (Diluted Average) (Quarter) stood at $113.3 million in 2022, then grew by 21.91% to $138.1 million in 2023, then grew by 0.46% to $138.8 million in 2024, then grew by 2.13% to $141.7 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $141.7 million for Q3 2025, versus $141.7 million for Q2 2025 and $141.7 million for Q1 2025.